Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the aberrant expansion of plasma cells within the bone marrow, as well as at extramedullary sites. Decades of scientific research are now beginning to unravel the intricate biology that underlies the pathophysiology of MM. In particular, the roles of cellular differentiation, molecular pathogenesis, and oncogenes involved in the natural history of MM are becoming clearer. This has enabled the identification of specific cytokines, adhesion molecules, and stromal cells that affect MM cell development, disease progression, and treatment responses. This review describes our current understanding regarding the biology of MM, and how this has led to a robust pipeline of novel therapeutic agents with the potential to overcome resistance to existing MM therapies and, therefore, further improve outcomes in patients with MM.

中文翻译：

---

多发性骨髓瘤：疾病的生物学。

多发性骨髓瘤（MM）是一种克隆性B细胞恶性肿瘤，其特征是浆细胞在骨髓内以及髓外部位异常扩增。现在数十年的科学研究开始揭示构成MM病理生理学基础的复杂生物学。特别是，MM的自然病史中涉及的细胞分化，分子发病机制和致癌基因的作用正在变得更加清晰。这使得能够识别影响MM细胞发育，疾病进展和治疗反应的特定细胞因子，粘附分子和基质细胞。这篇综述描述了我们目前对MM生物学的理解，以及这如何导致了强大的新型治疗药物的开发，并有可能克服对现有MM治疗的抗性，因此，